StreetInsider.com News Articles

ENvue Medical stock to move to OTC after Nasdaq delisting ruling

Tue, 15 Sep 2026 12:47:33 -0400

ENvue Medical, Inc. (NASDAQ: FEED) announced that the Nasdaq Hearings Panel denied its request for continued listing on the Nasdaq Capital Market, according to a press release issued Sept. 15, 2026.

Trading of the company's common stock on Nasdaq will be suspended, with shares set to begin trading on OTC Markets under the same ticker symbol, FEED, on Sept. 16, 2026.

The company said it is evaluating all available procedures and alternatives under Nasdaq Listing Rules, including a further appeal of the panel's decision.

"We are disappointed with the Panel's decision and are evaluating all available paths forward," said Doron Besser, M.D., Chief

ENvue Medical Provides Nasdaq Listing Update

Tue, 15 Sep 2026 12:45:00 -0400

TYLER, Texas, Sept. 15, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (Nasdaq: FEED) (“ENvue” or the “Company”), a medical technology company focused on innovative solutions for enteral feeding and therapeutic ultrasound, today announced that it has received a decision from the Nasdaq Hearings Panel (the “Panel”) denying the Company’s request for continued listing on The Nasdaq Capital Market. As a result, trading of the Company’s common stock will be suspended and will begin trading on the OTC Markets under the same stock symbol, ‘FEED’, on September 16, 2026.

The Panel’s decision does not affect ENvue’s

ENvue Medical Provides Nasdaq Listing Update

Tue, 15 Sep 2026 12:45:00 -0400

The Panel’s decision does not affect ENvue’s

ENvue Medical resumes U.S. shipments of PainShield device

Wed, 09 Sep 2026 08:32:40 -0400

ENvue Medical, Inc. (NASDAQ: FEED) announced it has resumed commercial shipments of its PainShield® therapeutic ultrasound device, manufactured in the United States, and has begun fulfilling open orders from Ultra Pain Products, Inc. (UPPI), its exclusive U.S. distribution partner.

The resumption follows the completion of a manufacturing transition that moved NanoVibronix production operations from Israel to the United States. Research and development for the NanoVibronix product portfolio remains based in Tel Aviv, Israel.

"Restoring PainShield production and commercial shipments was an immediate priority for us following a manufacturing disruption," said Doron Besser, MD, Chief Executive Officer of ENvue. "With U.S. production now

ENvue Medical Resumes U.S. Commercial Shipments of NanoVibronix PainShield® and Begins Fulfilling Open Distributor Orders

Wed, 09 Sep 2026 08:30:00 -0400

Now shipping to UPPI, ENvue's exclusive distribution partner, following completion of the Company's U.S. manufacturing transition

TYLER, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) -- ENvue Medical , Inc. (NASDAQ: FEED) (“ENvue” or the “Company”), a commercial-stage medical device company focused on real-time guided bedside feeding tube placement and therapeutic technologies, today announced that it has resumed commercial shipments of PainShield®, manufactured in the United States, and has begun fulfilling open orders from Ultra Pain Products, Inc. (“UPPI”), the Company’s exclusive U.S. distribution partner for the product.

The resumption of shipments marks an important

ENvue Medical Resumes U.S. Commercial Shipments of NanoVibronix PainShield® and Begins Fulfilling Open Distributor Orders

Wed, 09 Sep 2026 08:30:00 -0400

Now shipping to UPPI, ENvue's exclusive distribution partner, following completion of the Company's U.S. manufacturing transition

The resumption of shipments marks an important

ENvue Medical Selected to Exhibit ENvue™ Navigation Platform at Vizient Innovative Technology Exchange

Wed, 02 Sep 2026 08:30:00 -0400

TYLER, Texas, Sept. 02, 2026 (GLOBE NEWSWIRE) -- ENvue Medical (NASDAQ: FEED) (“ENvue” or the “Company”), a commercial-stage medical device company focused on real-time guided bedside feeding tube placement, today announced it has been selected to exhibit its ENvue™ Navigation Platform, a minimally invasive electromagnetic navigation system guiding feeding tube placement, at the Vizient® Innovative Technology Exchange. Vizient, the nation’s largest provider-driven healthcare performance improvement company, will hold the Exchange on September 24, 2026 in Las Vegas, Nevada.

The annual Innovative Technology Exchange offers selected suppliers the opportunity to

ENvue Medical Selected to Exhibit ENvue™ Navigation Platform at Vizient Innovative Technology Exchange

Wed, 02 Sep 2026 08:30:00 -0400

The annual Innovative Technology Exchange offers selected suppliers the opportunity to

ENvue Medical sets 1-for-12 reverse stock split effective Sept. 1

Fri, 28 Aug 2026 08:00:12 -0400

ENvue Medical, Inc. (NASDAQ: FEED) announced that a 1-for-12 reverse stock split of its common stock will take effect on September 1, 2026, with shares beginning to trade on the Nasdaq Capital Market on a post-split basis at market open that day under the existing ticker symbol "FEED" and a new CUSIP number, 63008J876.

Under the terms of the split, every 12 shares of common stock will be combined into one share, reducing the company's outstanding shares from approximately 11,084,616 to approximately 923,718. The number of authorized shares remains unchanged at 40,000,000.

No fractional shares will be issued. Any fractional shares resulting

ENvue Medical, Inc. Announces 1-for-12 Reverse Stock Split

Fri, 28 Aug 2026 08:00:00 -0400

TYLER, Texas, Aug. 28, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) ("ENvue" or the "Company"), a commercial-stage medical technology company, today announced that a reverse stock split of the Company’s issued and outstanding common stock, par value $0.001 per share (the “Common Stock”) at a ratio of 1-for-12 is expected to become effective on September 1, 2026. The Company's Common Stock will begin trading on the Nasdaq Capital Market on a post-split basis at the market open on September 1, 2026, under the Company's existing trading symbol "FEED", but will trade under a new CUSIP

ENvue Medical, Inc. Announces 1-for-12 Reverse Stock Split

Fri, 28 Aug 2026 08:00:00 -0400

ENvue Medical, Inc. Announces 1-for-12 Reverse Stock Split

Fri, 28 Aug 2026 08:00:00 -0400

ENvue Medical, Inc. Announces 1-for-12 Reverse Stock Split

Fri, 28 Aug 2026 08:00:00 -0400

ENvue Medical Announces Exclusive UroShield® Distribution Agreement with Minimum Purchase Commitments of Approximately $2.6 Million

Tue, 18 Aug 2026 08:30:00 -0400

Multi-year agreement with Peak Medical expands UroShield commercialization across the United Kingdom and Republic of Ireland

TYLER, Texas, Aug. 18, 2026 (GLOBE NEWSWIRE) -- ENvue Medical (NASDAQ: FEED) (“ENvue” or the “Company”), a commercial-stage medical device company, today announced a new exclusive distribution agreement with Peak Medical, a complete medical equipment solutions company, to expand commercial distribution of ENvue’s UroShield® device across the United Kingdom and Republic of Ireland. The agreement includes minimum purchase commitments of approximately $2.6 million over its initial term through December 31, 2029, creating a meaningful opportunity to expand market access and drive revenue growth

ENvue Medical Announces Exclusive UroShield® Distribution Agreement with Minimum Purchase Commitments of Approximately $2.6 Million

Tue, 18 Aug 2026 08:30:00 -0400

Multi-year agreement with Peak Medical expands UroShield commercialization across the United Kingdom and Republic of Ireland

ENvue Medical Announces Exclusive UroShield® Distribution Agreement with Minimum Purchase Commitments of Approximately $2.6 Million

Tue, 18 Aug 2026 08:30:00 -0400

Multi-year agreement with Peak Medical expands UroShield commercialization across the United Kingdom and Republic of Ireland

ENvue Medical Announces Exclusive UroShield® Distribution Agreement with Minimum Purchase Commitments of Approximately $2.6 Million

Tue, 18 Aug 2026 08:30:00 -0400

Multi-year agreement with Peak Medical expands UroShield commercialization across the United Kingdom and Republic of Ireland

Form 10-Q ENvue Medical, Inc. For: Jun 30

Mon, 17 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260817/26938776.html

Form 10-Q ENvue Medical, Inc. For: Jun 30

Mon, 17 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260817/26938776.html

Form NT 10-Q ENvue Medical, Inc. For: Jun 30

Fri, 14 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260814/26930828.html

Form NT 10-Q ENvue Medical, Inc. For: Jun 30

Fri, 14 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260814/26930828.html

Form 8-K ENvue Medical, Inc. For: Aug 14

Fri, 14 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260814/26930358.html

Form 8-K ENvue Medical, Inc. For: Aug 14

Fri, 14 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260814/26930358.html

ENvue Medical secures $50M equity facility for growth and acquisitions

Wed, 12 Aug 2026 08:36:18 -0400

ENvue Medical, Inc. (NASDAQ: FEED) announced it has entered into a securities purchase agreement with an institutional investor providing an equity facility of up to $50 million, subject to terms including stockholder approval.

The Tyler, Texas-based medical technology company said the facility is intended to support expansion of its technology platform and evaluation of strategic acquisitions and business development opportunities.

"We have a strong foundation in enteral navigation and a technology roadmap that we believe can take us further," said Doron Besser, CEO of ENvue Medical. "With greater financial flexibility, we believe we will be able to evaluate opportunities to acquire technologies,

ENvue Medical secures $50M equity facility for growth and acquisitions

Wed, 12 Aug 2026 08:36:18 -0400